BNT163 / BioNTech, University of Pennsylvania - LARVOL DELTA

BNT163-01: A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=318 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Simplex • Infectious Disease

Safety and Immunogenicity of BNT163, a Trivalent mRNA HSV Vaccine Candidate for Genital Herpes (IDWeek 2025) - No abstract available

Clinical • Infectious Disease

A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination with an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=308 | Recruiting | Sponsor: BioNTech SE | Trial completion date: Apr 2026 ➔ Oct 2026 | Trial primary completion date: Apr 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=288 | Recruiting | Sponsor: BioNTech SE | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=248 | Recruiting | Sponsor: BioNTech SE | N=108 ➔ 248 | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: BioNTech SE

Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Herpes Simplex • Infectious Disease

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (clinicaltrials.gov) - P1 | N=108 | Not yet recruiting | Sponsor: BioNTech SE

New P1 trial • Herpes Simplex • Infectious Disease